使用组织学参数预测肾小球疾病进展:来自中国肾活检队列研究的发现
该多中心回顾性队列研究纳入中国8家三级医院2004至2020年间接受自体肾活检的4,982例肾小球疾病患者,评估在临床数据基础上加入组织学慢性化评分能否改善疾病结局预测。结果显示,将慢性化评分与肾衰竭风险方程(KFRE)联合的模型在验证队列中预测2年疾病进展的AUROC为0.76(95%CI 0.65-0.87),优于KFRE模型(AUROC 0.68,95%CI 0.56-0.79),差异有统计学意义(P=0.04)。
要点
- 在肾小球疾病患者肾活检时,组织学慢性化评分联合KFRE模型可改善肾脏病进展的预测。
- 验证队列中联合模型预测2年疾病进展的AUROC为0.76(95%CI 0.65-0.87),KFRE模型为0.68(95%CI 0.56-0.79),P=0.04。
- 联合模型拟合更优,赤池信息准则更低,综合判别改善指数和净重分类改善指数显示重分类有显著改善。
核心结论
- 在肾小球疾病患者肾活检时,将组织学慢性化评分加入KFRE模型可改善肾脏病进展的预测。
研究设计与样本
- 多中心回顾性队列研究,纳入中国8家三级医院2004至2020年间接受自体肾活检的4,982例肾小球疾病患者。
- 推导队列3,488例,验证队列1,494例,中位随访31个月。
- 预测因素为组织学慢性改变4个类别的慢性化评分以及基线临床和人口学变量,采用多因素Cox比例风险模型。
主要发现
- 两个队列中共444例(8.9%)患者发生疾病进展。
- 验证队列中,联合慢性化评分与KFRE的模型预测2年疾病进展风险的AUROC为0.76(95%CI 0.65-0.87)。
- KFRE模型预测2年疾病进展风险的AUROC为0.68(95%CI 0.56-0.79),联合模型显著更优(P=0.04)。
- 联合模型拟合更优,赤池信息准则更低,综合判别改善指数和净重分类改善指数显示重分类有显著改善。
- 亚组和敏感性分析中观察到相似的预测性能改善。
关键数值与推荐
- 疾病进展定义为复合终点:肾衰竭或估算肾小球滤过率较活检时测量值下降≥40%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 选择偏倚。
- 随访时间相对较短。
- 缺乏外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Challenges in achieving valid risk prediction and stratification impede treatment decisions and clinical research design for patients with glomerular diseases. This study evaluated whether chronic histologic changes, when complementing other clinical data, improved the prediction of disease outcomes across a diverse group of glomerular diseases. STUDY DESIGN: Multicenter retrospective cohort study. SETTING & PARTICIPANTS: 4,982 patients with biopsy-proven glomerular disease who underwent native biopsy at 8 tertiary care hospitals across China in 2004-2020. NEW PREDICTORS & ESTABLISHED PREDICTORS: Chronicity scores depicted as 4 categories of histological chronic change, as well as baseline clinical and demographic variables. OUTCOME: Progression of glomerular disease defined as a composite of kidney failure or a ≥40% decrease in estimated glomerular filtration rate from the measurement at the time of biopsy. ANALYTICAL APPROACH: Multivariable Cox proportional hazard models. The performance of predictive models was evaluated by C statistic, time-dependent area under the receiver operating characteristic curve (AUROC), net reclassification index, integrated discrimination index, and calibration plots. RESULTS: The derivation and validation cohorts included 3,488 and 1,494 patients, respectively. During a median of 31 months of follow-up, a total of 444 (8.9%) patients had disease progression in the 2 cohorts. For prediction of the 2-year risk of disease progression, the AUROC of the model combining chronicity score and the Kidney Failure Risk Equation (KFRE) in the validation cohort was 0.76 (95% CI, 0.65-0.87); in comparison with the KFRE model (AUROC, 0.68 [95% CI, 0.56-0.79]), the combined model was significantly better (P = 0.04). The combined model also had a better fit, with a lower Akaike information criterion and a significant improvement in reclassification as assessed by the integrated discrimination improvements and net reclassification improvements. Similar improvements in predictive performance were observed in subgroup and sensitivity analyses. LIMITATIONS: Selection bias, relatively short follow-up, lack of external validation. CONCLUSIONS: Adding histologic chronicity scores to the KFRE model improved the prediction of kidney disease progression at the time of kidney biopsy in patients with glomerular diseases. PLAIN-LANGUAGE SUMMARY: Risk prediction and stratification remain big challenges for treatment decisions and clinical research design for patients with glomerular diseases. The extent of chronic changes is an important component of kidney biopsy evaluations in glomerular disease. In this large multicenter cohort including 4,982 Chinese adults undergoing native kidney biopsy, we evaluated whether histologic chronicity scores, when added to clinical data, could improve the prediction of disease prognosis for a diverse set of glomerular diseases. We observed that adding histologic chronicity scores to the kidney failure risk equation improved the prediction of kidney disease progression at the time of kidney biopsy in patients with glomerular diseases.
引用
- Zhang X, Luo F, Chen R, et al. Use of Histologic Parameters to Predict Glomerular Disease Progression: Findings From the China Kidney Biopsy Cohort Study. Am J Kidney Dis. 2022. PMID: 36252881. doi:10.1053/j.ajkd.2022.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。